TegoScience Inc - Asset Resilience Ratio

Latest as of December 2025: 49.64%

TegoScience Inc (191420) has an Asset Resilience Ratio of 49.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TegoScience Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩38.80 Billion
≈ $26.29 Million USD Cash + Short-term Investments

Total Assets

₩78.16 Billion
≈ $52.97 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how TegoScience Inc's Asset Resilience Ratio has changed over time. See net assets of TegoScience Inc for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down TegoScience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 191420 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩38.80 Billion 49.64%
Total Liquid Assets ₩38.80 Billion 49.64%

Asset Resilience Insights

  • Very High Liquidity: TegoScience Inc maintains exceptional liquid asset reserves at 49.64% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

TegoScience Inc Industry Peers by Asset Resilience Ratio

Compare TegoScience Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Theragen Etex Co.Ltd
KQ:066700
Pharmaceuticals 1.52%
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 4.82%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
Oscotec Inc
KQ:039200
Pharmaceuticals 61.00%
Caregen Co.Ltd
KQ:214370
Pharmaceuticals 4.58%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 13.09%
Huons Global Co. Ltd
KQ:084110
Pharmaceuticals 5.46%

Annual Asset Resilience Ratio for TegoScience Inc (2015–2025)

The table below shows the annual Asset Resilience Ratio data for TegoScience Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 49.64% ₩38.80 Billion
≈ $26.29 Million
₩78.16 Billion
≈ $52.97 Million
-2.42pp
2024-12-31 52.06% ₩27.34 Billion
≈ $18.53 Million
₩52.52 Billion
≈ $35.59 Million
+9.30pp
2023-12-31 42.76% ₩20.91 Billion
≈ $14.17 Million
₩48.91 Billion
≈ $33.15 Million
-0.67pp
2022-12-31 43.43% ₩22.31 Billion
≈ $15.12 Million
₩51.36 Billion
≈ $34.81 Million
+1.65pp
2021-12-31 41.78% ₩21.31 Billion
≈ $14.44 Million
₩51.00 Billion
≈ $34.56 Million
-3.79pp
2020-12-31 45.58% ₩22.97 Billion
≈ $15.57 Million
₩50.40 Billion
≈ $34.16 Million
-0.32pp
2019-12-31 45.90% ₩22.29 Billion
≈ $15.11 Million
₩48.57 Billion
≈ $32.91 Million
+22.22pp
2018-12-31 23.67% ₩11.26 Billion
≈ $7.63 Million
₩47.56 Billion
≈ $32.23 Million
+1.76pp
2017-12-31 21.92% ₩10.43 Billion
≈ $7.07 Million
₩47.59 Billion
≈ $32.25 Million
-23.31pp
2016-12-31 45.22% ₩20.19 Billion
≈ $13.68 Million
₩44.64 Billion
≈ $30.25 Million
+33.58pp
2015-12-31 11.65% ₩3.00 Billion
≈ $2.03 Million
₩25.76 Billion
≈ $17.46 Million
--
pp = percentage points

About TegoScience Inc

KQ:191420 Korea Pharmaceuticals
Market Cap
$68.13 Million
₩100.53 Billion KRW
Market Cap Rank
#20673 Global
#1244 in Korea
Share Price
₩12450.00
Change (1 day)
-1.03%
52-Week Range
₩11620.00 - ₩19790.00
All Time High
₩71600.00
About

TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.